Catherine Scholz joined Kura Oncology in 2015 bringing extensive industry experience in strategic drug development, clinical pharmacology, multidisciplinary global team leadership and portfolio evaluation. Dr. Scholz has advanced both small molecules and biologic compounds through streamlined integrated development plans incorporating translational approaches and diagnostics for early proof of concept to realize accelerated development opportunities. Prior to joining Kura Oncology, she served as Immunology Program Leader at EMD Serono, Inc., the biopharmaceutical subsidiary in the United States of Merck KGaA, Darmstadt, Germany. In this role, she was responsible for program development strategy, portfolio advancement and asset value ensuring alignment with the Immunology and Immuno-Oncology business plans. From 2008 – 2013, Dr. Scholz held roles of increasing responsibility in Clinical Pharmacology and Global Team Leadership at Millennium: The Takeda Oncology Company. She began her industry career at Bayer Schering Pharma (Berlin, Germany). Dr. Scholz received both her Bachelor of Science and Doctor of Pharmacy degrees from Rutgers University. She received post-doctoral fellowship training in clinical pharmacology at the University of Texas, MD Anderson Cancer Center.